Boston Scientific Corporation $BSX Stake Lowered by Schroder Investment Management Group

Key Points

• Schroder Investment Management trimmed its Boston Scientific stake by 6.6% to 7.81 million shares (about $762.6M), making BSX its 29th largest holding while institutional investors own roughly 89.1% of the stock.
• Wall Street analysts have cut price targets (notably TD Cowen, Citigroup, JPMorgan and Wells Fargo), leaving a MarketBeat consensus of a "Moderate Buy" with a $108.36 average target.
• Boston Scientific slightly beat EPS expectations ($0.80 vs. $0.78) with revenue of $5.29B (+15.9% year-over-year) and set FY2026 guidance of $3.43–3.49 EPS, while the stock trades near its 52-week low (~$71) and was down about 2.4%.

Schroder Investment Management Group trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 6.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,810,918 shares of the medical equipment provider's stock after selling 552,139 shares during the period. Boston Scientific comprises approximately 0.6% of Schroder Investment Management Group's portfolio, making the stock its 29th biggest holding. Schroder Investment Management Group owned about 0.53% of Boston Scientific worth $762,580,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Steph & Co. acquired a new stake in shares of Boston Scientific during the 3rd quarter valued at about $25,000. Financial Consulate Inc. bought a new position in Boston Scientific during the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $26,000. Finally, United Community Bank grew its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. TD Cowen cut their price target on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. Citigroup lowered their target price on shares of Boston Scientific from $130.00 to $102.00 and set a "buy" rating on the stock in a research report on Thursday, February 5th. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $135.00 to $100.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. National Bank Financial set a $115.00 price target on Boston Scientific in a research note on Monday, February 2nd. Finally, Wells Fargo & Company lowered their price objective on Boston Scientific from $125.00 to $94.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $108.36.

Boston Scientific Stock Down 2.4%

BSX stock opened at $71.24 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a 50-day moving average of $85.03 and a two-hundred day moving average of $94.47. The stock has a market capitalization of $105.71 billion, a price-to-earnings ratio of 36.72, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a 52-week low of $70.75 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.